eprintid: 10198752
rev_number: 16
eprint_status: archive
userid: 699
dir: disk0/10/19/87/52
datestamp: 2024-10-22 16:45:24
lastmod: 2025-02-10 11:23:06
status_changed: 2024-10-22 16:45:24
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Del Galdo, Francesco
creators_name: Lescoat, Alain
creators_name: Conaghan, Philip G
creators_name: Bertoldo, Eugenia
creators_name: Čolić, Jelena
creators_name: Santiago, Tânia
creators_name: Suliman, Yossra A
creators_name: Matucci-Cerinic, Marco
creators_name: Gabrielli, Armando
creators_name: Distler, Oliver
creators_name: Hoffmann-Vold, Anna-Maria
creators_name: Castellví, Ivan
creators_name: Balbir-Gurman, Alexandra
creators_name: Vonk, Madelon
creators_name: Ananyeva, Lidia
creators_name: Rednic, Simona
creators_name: Tarasova, Anna
creators_name: Ostojic, Pedrag
creators_name: Boyadzhieva, Vladimira
creators_name: El Aoufy, Khadija
creators_name: Farrington, Sue
creators_name: Galetti, Ilaria
creators_name: Denton, Christopher P
creators_name: Kowal-Bielecka, Otylia
creators_name: Mueller-Ladner, Ulf
creators_name: Allanore, Yannick
title: EULAR recommendations for the treatment of systemic sclerosis: 2023 update
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G90
keywords: Connective Tissue Diseases, Pulmonary Arterial Hypertension, Pulmonary Fibrosis, Scleroderma, Systemic, Therapeutics
note: © 2024 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
abstract: OBJECTIVES: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. METHODS: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. RESULTS: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. CONCLUSION: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years.
date: 2025-01
date_type: published
publisher: BMJ
official_url: https://doi.org/10.1136/ard-2024-226430
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2327847
doi: 10.1136/ard-2024-226430
medium: Print-Electronic
pii: ard-2024-226430
lyricists_name: Denton, Christopher
lyricists_id: CPDEN87
actors_name: Denton, Christopher
actors_id: CPDEN87
actors_role: owner
funding_acknowledgements: EULAR recommendation grant QoC 010 [EULAR]
full_text_status: public
publication: Annals of the Rheumatic Diseases
volume: 84
pagerange: 29-40
event_location: England
citation:        Del Galdo, Francesco;    Lescoat, Alain;    Conaghan, Philip G;    Bertoldo, Eugenia;    Čolić, Jelena;    Santiago, Tânia;    Suliman, Yossra A;                                                                             ... Allanore, Yannick; + view all <#>        Del Galdo, Francesco;  Lescoat, Alain;  Conaghan, Philip G;  Bertoldo, Eugenia;  Čolić, Jelena;  Santiago, Tânia;  Suliman, Yossra A;  Matucci-Cerinic, Marco;  Gabrielli, Armando;  Distler, Oliver;  Hoffmann-Vold, Anna-Maria;  Castellví, Ivan;  Balbir-Gurman, Alexandra;  Vonk, Madelon;  Ananyeva, Lidia;  Rednic, Simona;  Tarasova, Anna;  Ostojic, Pedrag;  Boyadzhieva, Vladimira;  El Aoufy, Khadija;  Farrington, Sue;  Galetti, Ilaria;  Denton, Christopher P;  Kowal-Bielecka, Otylia;  Mueller-Ladner, Ulf;  Allanore, Yannick;   - view fewer <#>    (2025)    EULAR recommendations for the treatment of systemic sclerosis: 2023 update.                   Annals of the Rheumatic Diseases , 84    pp. 29-40.    10.1136/ard-2024-226430 <https://doi.org/10.1136/ard-2024-226430>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10198752/7/Denton_EULAR%20recommendations%20for%20the%20treatment%20of%20systemic%20sclerosis_VoR.pdf